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Abstrak 
Sindrom Koroner Akut (SKA) merupakan penyakit kardiovaskuler yang utama 
menyebabkan kematian hingga tahun 2020. Tingginya angka morbiditas dan mortalitas 
pasien SKA maka diperlukan strategi yang meringkas standar tatalaksana terapi yang 
dikenal dengan clinical pathway. Penelitian ini bertujuan untuk mengetahui apakah 
terdapat hubungan pelaksanaan clinical pathway berdasarkan lembar penilaian clinical 
pathway terhadap lama rawat inap dan kejadian fatal pada pasien SKA. 
Penelitian ini merupakan penelitian cross sectional pada pasien SKA 
(NSTEMI/STEMI) yang dirawat di ICCU RSUP Dr. Sardjito Yogyakarta. Bahan  yang  
digunakan  adalah catatan  medik  pasien  SKA. Alat yang digunakan adalah lembar 
pengumpul data dan lembar penilaian clinical pathway SKA. Pengambilan data secara 
retrospektif (Februari – Juli 2014) dan prospektif (Agustus – September 2014). Subyek 
penelitian berjumlah 102 pasien yang terbagi 2 kelompok (49 pasien tanpa variasi dan 53 
pasien variasi) berdasarkan pada lembar penilaian clinical pathway. Variasi diperoleh dari 
ketidaksesuaian berjumlah satu/lebih dari tatalaksana terapi pada lembar penilaian clinical 
pathway dalam 24 jam pertama perawatan di ICCU. Analisa data meliputi analisa 
hubungan lama rawat inap terhadap pelaksanaan clinical pathway pada kedua kelompok 
menggunakan uji chi-square dan analisa hubungan kejadian fatal (kematian, gagal jantung, 
stroke, dan reinfark) terhadap pelaksanaan clinical pathway pada kedua kelompok 
menggunakan uji Fisher Exact Test. 
Hasil penelitian ini menunjukkan bahwa pelaksanaan clinical pathway yang 
berdasarkan lembar penilaian clinical pathway tidak terdapat hubungan terhadap lama 
rawat inap dan angka kejadian fatal pada pasien SKA (p>0,05) di ICCU Dr. Sardjito 
Yogyakarta dikarenakan lembar penilaian clinical pathway SKA kurang informatif dan 
secara umum tatalaksana terapi dalam 24 jam pertama telah sesuai dengan clinical 
pathway pasien SKA. 
 
Kata Kunci : Clinical Pathway, Lama Rawat Inap, Kejadian Fatal, Sindroma Koroner Akut 
 
Abstract 
 
Acute Coronary Syndrome (ACS) is a cardiovascular disease that become a major 
cause of death until 2020. Standard strategy which summarize the treatment of therapy 
known as clinical pathways is required caused by the high rate of morbidity and mortality 
of patients with ACS. This study aimed to determine the relationship of the clinical pathways 
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implementation based on the clinical pathway assessment sheet to the length of stay and 
number of fatal events in patients with acute coronary syndrome (ACS). 
This study was a cross sectional study in patients with ACS (NSTEMI/STEMI) 
treated in ICCU Hospital Dr. Sardjito. The materials used were ACS patient medical 
records. The tool used is a data collection sheet and clinical pathways assessment sheet. 
Making retrospective (February - July 2014) and prospective (August - September 2014). 
The research subjects are 102 patients were divided into 2 groups (49 patients without 
variation and 53 patients with variations) based on clinical pathways assessment sheet. 
Variations obtained from the discrepancy amounted to one/more of the therapeutic 
management of clinical pathways assessment sheet in the first 24 hours of treatment in 
ICCU. Data analysis includes analysis of long hospitalization relationship to the 
implementation of clinical pathways in the two groups using the chi-square test and analysis 
of the relationship number of fatal events (death, heart failure, stroke, and reinfarction) on 
the implementation of clinical pathways in the two groups using Fisher's exact test. 
The results of this study indicate that the implementation of clinical pathways based 
on clinical pathways assessment sheet there is no relationship to the length of stay and the 
number of fatal events in patients with ACS (p>0,05) in ICCU Dr. Sardjito due ACS 
assessment sheet clinical pathways are less informative and general management of 
therapy within the first 24 hours in accordance with the patient's clinical pathways for ACS. 
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Introduction 
Acute Coronary Syndrome 
(ACS) is one of main clinical 
manifestations of coronary heart 
disease (CHD) and major cause of 
death  (Departemen Kesehatan, 
2006). ACS consists of myocardial 
infarction with or without ST segment 
elevation is threatening disorders 
with morbidity and high mortality rate 
despite treatment of ACS  procedures 
have been evolved (Kolansky, 2009). 
Globally in 2010, coronary heart 
diseases (CHD), one of them is ACS, 
became the first cause of death in 
developing countries, replacing the 
death due to infection. Estimation in 
worldwide, CHD in 2020 will became 
the first commonest killer which 
amounted to 36% of all deaths, the 
rate is two times higher than the 
death rate from cancer (Departemen 
Kesehatan, 2006). 
Selection of drug therapy in 
the treatment of ACS among other 
anti-ischemic, anticoagulants, 
antiplatelet agents, thrombolytic, as 
well as other drugs such as ACE 
inhibitors and statins (Braunwald 
dkk., 2002). In addition to drug 
administration, guidance on 
emergency revascularization by the 
European Society of Cardiology 
mentions that revascularization given 
STEMI patients are emergency, while 
in patients with NSTEMI is urgency 
that revascularization can be 
performed within 24 hours and do not 
exceed the time from 72 hours after 
the episode of ACS (Windecker dkk., 
2014). 
Therapeutic management 
strategies in ACS patients that take 
place in an optimal management 
strategies, effective, and efficient is 
required because of the high rate of 
morbidity, mortality, and costs in 
patients with ACS (Departemen 
Kesehatan, 2006). Variation of the 
therapeutic management is needed 
because each patient has different 
conditions when the body reacts to 
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the drug and disease. But 
sometimes, the variation is not 
necessary so implementation of 
clinical pathways is needed (Rahma, 
2013). Giving revascularization by 
percutaneous coronary interventionn 
(PCI) can improve clinical outcomes 
of ACS being able to reduce the 
mortality and morbidity rate 
(Blackman dkk., 2003). 
Clinical pathways help 
patients with clinical or circumstances 
of a particular diagnosis through 
clinical experience or the desired 
outcome (Bor, 2011). Clinical 
pathways have been widely applied 
by health services in hospitals that 
one of its goals is to reduce variation 
in therapy based on pre-existing 
guidelines in order to improve the 
clinical outcome of patients with ACS 
(Rotter et al., 2010). The enactment 
of clinical pathways for patients with 
ACS in the RSUP Dr. Sardjito 
Yogyakarta needs an evaluation. 
One of this evaluation is analyzing the 
relationship of clinical pathways 
implementation based on the clinical 
pathways assessment sheet to length 
of stay and number of fatal events in 
patients with ACS in the ICCU RSUP 
Dr. Sardjito Yogyakarta. 
This study aimed to determine 
the relationship of the clinical 
pathways implementation based on 
the clinical pathway assessment 
sheet to the length of stay and 
number of fatal events in patients with 
acute coronary syndrome (ACS). 
 
Materials and Methods 
This study was an analytical 
observational study with cross 
sectional design. Data were collected 
retrospectively in the month of 
February to September 2014 and 
prospectively in August-September 
2014. Measurement of length of stay 
and  number of fatal events done at 
one time during the study period and 
the relationship of variation clinical 
pathways implementation to the 
length of  stay and the number of fatal 
events in patients with ACS were 
analyzed based on the clinical 
pathways assessment sheet. This 
research subjects are patients who 
are appropriate with the inclusion and 
exclusion criteria. Inclusion criteria 
are ACS patients in ≥18 years old and 
an exclusion criteria are patients with 
incomplete medical records and there 
are no clinical pathways assessment 
sheet of ACS during during 
hospitalization in ICCU RSUP Dr. 
Sardjito Yogyakarta. The research 
subjects are 102 patients with ACS 
were divided into 2 groups (49 
patients in no variation and 53 
patients in variation). 
The variables of this study 
consists of the independent 
variables. They are ACS patients 
(STEMI or NSTEMI). Dependent 
variable is the clinical outcomes of 
patients consisting of the length of 
stay and the number of fatal events 
(hospital in-mortality, heart failure, 
stroke, and myocardial reinfarction). 
As for the external variables include 
patient characteristics (age, sex, risk 
factors, history of coronary heart 
disease (CHD), diagnostics, and drug 
use during the first 24 hours). 
The data that have been 
taken were analyzed. Data analysis 
includes the analysis of the 
characteristics of ACS patients, 
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analysis of each stage of the 
implementation of clinical pathways 
in the two groups using the chi-
square goodness-of-fit test, analysis 
of length  stay relationship to the 
implementation of clinical pathways 
in the two groups using the chi-
square test, and analysis of 
relationship between number of fatal 
events of clinical pathway 
implementation in both groups using 
the Fisher Exact Test. 
 
Results and Discussion 
1. Characteristic of Studies Objects. 
Research subjects are 
dominated by men (82% in no 
variation and to 77% in variation) with 
the highest prevalence in the age 
group <60 years (61%  in no variation 
and 57% in variation), has a risk 
factor of smoking is mostly done by 
males (68.63%), and had a diagnosis 
of STEMI (84% in no variation and 
83% in variation). The whole basic 
characteristics of the study subjects 
have different value, but the basic 
characteristics of the two research 
subjects groups did not have a 
statistically significant difference 
value (p> 0.05). The most widely 
drugs that used by ACS patients 
within the first 24 hours are aspirin 
(81.37%), clopidogrel (81.37%), 
heparin (93.14%), atorvastatin 
(89.22%), captopril (77.45%), 
isosorbide dinitrate (ISDN) (83.33%), 
alprazolam (67.65%), and glycerin as 
a laxative (48.04%). 
 
 
 
2. Clinical Pathway Implementation 
to Acute Coronary Syndrome 
Patients 
a. Implementation of Clinical 
Assessment  
Overall the 
implementation of both clinical 
assement on DPJP 
examination (doctor in charge 
of service) and a vital sign 
checks in clinical pathways 
assessment sheet does not 
have relevance in both groups 
of research subjects (p>0,05). 
The big difference in the 
number of both groups because 
the study subjects were 13 
cases in the group variations in 
the patient's clinical pathways 
assessment sheet ACS there is 
no written reasons in DPJP 
examination column and 1 case 
in the assessment sheet on the 
column clinical pathways vital 
signs, after examination was 
made into the medical record 
patients this is due to the lack of 
signatures by DPJP so 
necessary communication 
between healthcare 
practitioners in documenting 
the treatment of therapy on 
clinical pathways ACS 
assessment sheets to support 
the implementation of clinical 
pathways in patients with ACS 
in ICCU Dr. Sardjito. 
b. Implementation of Supporting 
Investigation 
All of supporting 
investigation in this study have 
same value in both groups. 
Except for troponin I/CKMB, 
there were 3 cases that were 
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not conducted investigations of  
troponin I / T in the clinical 
pathways assessment sheet. 
But after a search of ACS 
patients medical records, there 
were an inspection sheet of 
troponin I and CKMB for 
patients within 24 hours of 
treatment when he first entered 
in the ICCU. Based on in this 
study, there is no good 
documentation on clinical 
pathways assessment sheet for 
patients with ACS. 
c. Implementation of Therapy 
Overall management of 
both the drug therapy and 
provision of revascularization in 
patients with acute coronary 
syndrome was based on clinical 
pathways assessment form 
does not have a statistically 
significant value by using chi-
square goodness-of-fit test for 
two groups of study subjects 
(p> 0.05). 
In subanalisis of 
revascularization in patients 
with STEMI are 85 subjects 
who had a diagnosis of STEMI; 
27 patients (32%) do 
revascularization, this is in 
accordance with the 
standards/not vary, while as 
many as 58 patients (68%) did 
not do 
revascularization/variations 
either thrombolytic and PCI for 
treatment in ICCU is written in 
the patient record sheet of 
ACS. Given the type of 
revascularization with onset <6 
hours is a thrombolytic 
(streptokinase) of 15 patients 
(56%), while revascularization 
with onset 6-12 hours is PCI as 
many as 12 patients (44%). 
Patients with ST-segment 
elevation ACS were not 
performed emergency 
revascularization by 52% had 
onset> 12 hours. A total of 8 
patients (14%) of the patients 
were not given the current 
emergency revascularization 
treatment in ICCU during the 
first 24 hours because have 
gained previous 
revascularization in health care 
that is as much as 5 patients 
had onset <6 hours with 
thrombolytic and 3 patients had 
onset> 12 hours with PCI. 
 
3. Length of Stay of Acute Coronary 
Syndrome Patients 
Distribution of  length of stay 
of ACS patients in this study are 
divided into 2 groups: <5 days and> 5 
days. The division of this group is 
based on the average length of stay 
(5.54 days ± 3.01 days) in ICCU 
RSUP Dr. Sardjito Yogyakarta. This 
study indicate that the length of stay 
group <5 days  is higher (57%) than 
the  group with length of stay > 5 days 
(43%), both are with no variation or 
with  variation. The results of 
statistical analysis in this study shows 
that length of stay is not affected by 
the implementation of clinical 
pathways in patients with ACS in 
ICCU RSUP Dr. Sardjito Yogyakarta 
(p> 0.05). It is caused by most of the 
therapeutic management of patients 
with ACS in ICCU RSUP Dr. Sardjito 
Yogyakarta are accordance with 
clinical pathways that have been 
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agreed. It makes the length of stay 
that required  by ACS patients in 
ICCU RSUP Dr. Sardjito Yogyakarta 
is short. 
The existence of an 
emergency revascularization in 
patients with STEMI from study 
subjects showed that patients with 
revascularization / without variation) 
more has length of stay <5 days 
(67%), whereas in patients with 
STEMI without revascularization / 
variations have more length of stay> 
5 days (52%). Analysis of 
revascularization on length of stay 
have different values are statistically 
significant (p> 0.05) were statistically 
tested using the chi-square test. 
 
4. Number of Fatal Events of Acute 
Coronary Syndrome Patients 
Implementation of clinical 
pathways on the number of fatal 
events in this study indicate there is 
no significant difference (p>0.05), so 
that the number of fatal events in this 
study were not affected by the 
implementation of clinical pathways 
in patients with ACS in the ICCU 
RSUP Dr. Sardjito Yogyakarta. It 
caused by clinical pathways 
assessment sheets are used as a tool 
in this study does not provide 
sufficient information clearly. Beside 
that, the management of therapy in 
this study, especially the treatment of 
therapy within the first 24 hours, have 
been in accordance with the clinical 
pathway for ACS patients that has 
been agreed by mustidispliner in the 
department of health RSUP Dr. 
Sardjito Yogyakarta. 
Prior research, 
revascularization by PCI can reduce 
the number of fatal events (death, 
stroke, myocardial reinfarction) in 
STEMI patients by 2.7% compared to 
STEMI patients who did not get PCI 
revascularization which amounted to 
6.5% (p=0.039) (Bench dkk., 2013). 
Due to without revascularization of 
the fatal incident in STEMI patients as 
a whole has a number greater than 
STEMI patients given the kemtian 
revascularization (9%), heart failure 
(3%), stroke (2%) and reinfarction 
(3%), but do not have different values 
are statistically significant between 
patients who received 
revascularization with patients who 
did not receive revascularization 
(p>0.05) were tested using the 
statistical test of Fisher Exact Test. 
 
Conclusion 
Based on the results of this 
study, it can be concluded that there 
is no relationship between clinical 
pathways implementation based on 
the clinical pathway assessment 
sheet to the length of stay and the 
number of fatal events in patients with 
ACS. 
In subanalisis, emergency 
revascularization in patients with 
STEMI has long hospitalization <5 
days (67%), while the STEMI patients 
without revascularisation have length 
of stay > 5 days (52%). A Fatal event 
rates without revascularisation in 
STEMI were greater, amounting to 
9% for mortality, 3% for heart failure, 
2% for stroke and 3% for the 
occurrence of reinfarction, whereas 
STEMI with revascularization just 
inflict death (4%). 
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